Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine|
|Abstract:||Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.|
|Inventor(s):||Hind; Harry (Los Altos, CA)|
|Assignee:||Hind Health Care, Inc. (Los Altos, CA)|
1. A method for the relief of pain of a host suffering from herpes zoster or post-herpetic neuralgia by inducing analgesia for an extended period of time, said method
maintaining lidocaine intradermally at a concentration sufficient to induce analgesia, at the site of said pain;
whereby said pain is relieved by said lidocaine.
2. A method according to claim 1, wherein said maintaining comprises:
applying a gel or patch comprising from about 1 to 20 weight % lidocaine in a vehicle providing for intradermal delivery.
3. A method according to claim 2, wherein said gel or patch comprises an occlusive dressing, wherein said occlusive dressing is porous or non-porous.
4. A method according to claim 1, wherein said lidocaine is present in partial amount as the free base.
5. A method for the relief of pain of a host suffering from herpes zoster or post-herpetic neuralgia by inducing analgesia for an extended period of time, said method comprising:
applying, to a skin surface at the site of said pain, a gel or patch comprising from about 1 to 20 weight % lidocaine in a vehicle for transdermal delivery of said lidocaine to the dermal layer of said skin;
maintaining said gel or patch at said site for at least 8 hours to induce analgesia, but not anesthesia;
whereby said pain is relieved by said lidocaine for at least about 8 hours.
6. A method according to claim 5, wherein said gel or patch is maintained for greater than 8 hours and not more than about 24 hours.
7. A method according to claim 5, wherein said vehicle comprises from about 70 to 90 weight % of a polyol vehicle.
8. A method according to claim 7, wherein said polyol is propylene glycol.
9. A gel formulation for treatment of pain from herpes zoster or post-herpetic neuralgia comprising:
from about 70 to 90 weight % of propylene glycol;
from about 1 to 20 weight % of lidocaine;
from about 2 to 20 weight % of a non-ionic surfactant comprising physiologically acceptable sorbitan esters;
from about 0.1 to 5 weight % of a physiologically acceptable gelling agent; and
not more than about a total of 10 weight % of physiologically acceptable excipients.
10. A gel formulation according to claim 9, wherein said lidocaine is present in from about 5 to 10% and said gelling agent is a neutralized polyacrylic acid.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.